PET Imaging for Gynecologic Malignancy.
- Author:
Kyoung Sook WON
1
Author Information
1. Department of Nuclear Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Korea. won@dsmc.or.kr
- Publication Type:Review
- Keywords:
18-fluorodeoxyglucose;
gynecologic malignancy;
positron emission tomography;
positron emission tomography/computed tomography
- MeSH:
Biopsy;
Drug Therapy;
Ovarian Neoplasms;
Positron-Emission Tomography;
Positron-Emission Tomography and Computed Tomography;
Prognosis;
Recurrence;
Uterine Cervical Neoplasms
- From:Hanyang Medical Reviews
2007;27(4):59-65
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The utility of positron emission tomography (PET) in gynecologic malignancy has increased rapidly in recent years. This review examines publications in this area. PET scans in gynecologic malignancy are mostly performed using F-18 FDG. It is valuable in primary staging of untreated advanced cervical cancer, for post-treatment unexplained tumor marker elevation, and restaging of potentially curable recurrent cervical cancer. However, its value in early-stage cervical cancer is limited. In ovarian cancer, sequential imaging predicts response to neoadjuvant chemotherapy and survival. It is also very useful when increases in CA 125 or CT/MRI defined recurrence is noted, but biopsy deemed infeasible. The role of PET or PET/CT has evolved from a iagnostic tool into a potential indicator of response to treatment and prognosis. Evaluating PET or PET/CT using clinical impact is an attractive new endpoint.
